Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025)

Protalix BioTherapeutics' (PLX) quarterly Return on Invested Capital came in at 0.0% in Q1 2025, little changed year-on-year from 0.0% in Q1 2024, and up 99.32% quarter-over-quarter from 0.0% in Q4 2024.

Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025) Analysis & Trends

Protalix BioTherapeutics' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.0% for Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.00%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.04%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Protalix BioTherapeutics 190.95 Mn 180.16 Mn 29.62 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2025 0.00%
Dec 31, 2024 0.00%
Sep 30, 2024 0.00%
Jun 30, 2024 0.00%
Mar 31, 2024 0.00%
Dec 31, 2023 0.00%